Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 578.,Rini BI, Huseni M, Atkins MB, et al. Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). ESMO 2018, abstract LBA31.
Nieuwe financiële impuls voor Oncode Institute om de code van kanker te blijven kraken
apr 2023 | Borstkanker, Bot en wekedelentumoren, Dermato-oncologie, Gynaecologische oncologie, Hoofd-halsoncologie, Immuuntherapie, Longoncologie, Maag-darm-leveroncologie, Neuro-oncologie, Uro-oncologie